Correspondence and General Collaboration Papers 1991

Early proposals by Marc Feldmann and Ravinder Maini to pharmaceutical companies and colleagues for research into TNF as a therapeutic target in rheumatoid arthritis. The item also covers the very early developments with Centocor for Phase I anti-TNF patient trials.

See SA/KET/A/2/1 for an overview of the Centocor correspondence, general papers and list of main correspondence contributors.

See SA/KET/A/1 for papers on Centocor sponsored clinical studies/trials.

Item contains some duplicate correspondence.

1989-1991

1 file (in 2 parts)

This item requires facilitated access. Email library@wellcomecollection.org to request an appointment.